Novel carbonic anhydrase inhibitors

Future Medicinal ChemistryVol. 13, No. 22 EditorialNovel carbonic anhydrase inhibitorsClaudiu T SupuranClaudiu T Supuran *Author for correspondence: E-mail Address: claudiu.supuran@unifi.ithttps://orcid.org/0000-0003-4262-0323Neurofarba Department, Pharmaceutical & Nutraceutical Section, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, Florence, 50019, ItalyPublished Online:9 Sep 2021https://doi.org/10.4155/fmc-2021-0222AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: carbonic anhydraseshypoxic tumorsinhibition mechanismsinhibitorspharmacological applicationsReferences1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 7(2), 168–181 (2008).Crossref, Medline, CAS, Google Scholar2. Supuran CT. Structure and function of carbonic anhydrases. Biochem. J. 473(14), 2023–2032 (2016).Crossref, Medline, CAS, Google Scholar3. Hirakawa Y, Senda M, Fukuda K et al. Characterization of a novel type of carbonic anhydrase that acts without metal cofactors. BMC Biol. 19(1), 105 (.2021).Crossref, Medline, CAS, Google Scholar4. Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin. Sci. (Lond.) 135(10), 1233–1249 (2021).Crossref, Medline, CAS, Google Scholar5. Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol. Rev. 47(4), 595–781 (1967).Crossref, Medline, CAS, Google Scholar6. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 27(6), 759–772 (2012).Crossref, Medline, CAS, Google Scholar7. Parkkila S, Lasota J, Fletcher JA et al. Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod. Pathol. 23(5), 743–750 (2010).Crossref, Medline, CAS, Google Scholar8. van Karnebeek CD, Sly WS, Ross CJ et al. Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood. Am. J. Hum. Genet. 94(3), 453–461 (2014).Crossref, Medline, CAS, Google Scholar9. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J. Med. Chem. 42(14), 2641–2650 (1999).Crossref, Medline, CAS, Google Scholar10. Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin. Drug Discov. 15(6), 671–686 (2020).Crossref, Medline, CAS, Google Scholar11. Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med. Res. Rev. 40(6), 2485–2565 (2020).Crossref, Medline, CAS, Google Scholar12. Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J. Enzyme Inhib. Med. Chem. 31(3), 345–360 (2016).Crossref, Medline, CAS, Google Scholar13. D'Ambrosio K, Carradori S, Monti SM et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem. Commun. (Camb). 51(2), 302–305 (2015).Crossref, Medline, Google Scholar14. Berrino E, Michelet B, Martin-Mingot A, Carta F, Supuran CT, Thibaudeau S. Modulating the efficacy of carbonic anhydrase inhibitors through fluorine substitution. Angew. Chem. Int. Ed. Engl. 60, 2–17 (2021).Crossref, Google Scholar15. Nocentini A, Angeli A, Carta F et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J. Enzyme Inhib. Med. Chem. 36(1), 561–580 (2021).Crossref, Medline, CAS, Google Scholar16. McDonald PC, Chia S, Bedard PL et al. A Phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am. J. Clin. Oncol. 43(7), 484–490 (2020).Crossref, Medline, CAS, Google Scholar17. Dettori I, Fusco I, Bulli I et al. Protective effects of carbonic anhydrase inhibition in brain ischaemia in vitro and in vivo models. J. Enzyme Inhib. Med. Chem. 36(1), 964–976 (2021).Crossref, Medline, CAS, Google Scholar18. Provensi G, Carta F, Nocentini A et al. A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer’s disease. Int. J. Mol. Sci. 20(19), 4724 (2019).Crossref, CAS, Google Scholar19. Supuran CT, Nocentini A, Yakubova E, Savchuk N, Kalinin S, Krasavin M. Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida®) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms. J. Enzyme Inhib. Med. Chem. 36(1), 1056–1060 (2021).Crossref, Medline, CAS, Google Scholar20. Bua S, Lucarini L, Micheli L et al. Bioisosteric development of multitarget nonsteroidal anti-inflammatory drug-carbonic anhydrases inhibitor hybrids for the management of rheumatoid arthritis. J. Med. Chem. 63(5), 2325–2342 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 13, No. 22 Follow us on social media for the latest updates Metrics Downloaded 194 times History Received 29 July 2021 Accepted 31 August 2021 Published online 9 September 2021 Published in print November 2021 Information© 2021 Newlands PressKeywordscarbonic anhydraseshypoxic tumorsinhibition mechanismsinhibitorspharmacological applicationsFinancial & competing interests disclosureResearch from the author’s laboratory was financed by the Italian Ministry for University and Research (MIUR), grants PRIN prot. 2017XYBP2R and FISR2019_04819 BacCAD. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download